J&J To Meet With FDA To Resolve Status Of Duragesic Generics
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson will meet with FDA shortly to discuss the issues surrounding Mylan's ANDA to market a generic version of Duragesic (transdermal fentanyl)
You may also be interested in...
“Authorized” Duragesic Generic Would Not “Make Sense,” Mylan Says
Mylan does not anticipate an "authorized" generic for Johnson & Johnson's Duragesic (fentanyl transdermal system)
“Authorized” Duragesic Generic Would Not “Make Sense,” Mylan Says
Mylan does not anticipate an "authorized" generic for Johnson & Johnson's Duragesic (fentanyl transdermal system)
J&J Duragesic Patent Upheld; Pediatric Exclusivity Dispute Will Determine Timing Of Mylan Generic
Mylan claims it should be able to launch in July; J&J says the generic is blocked by pediatric exclusivity until January 2005. Mylan says J&J failed to sue within statutory 45-day period and so forfeits pediatric exclusivity protection.